Report Summary
Eternity Insights can provide a deep dive research report highlighting the market and competitive in-telligence across the key segments of the market. The report also considers the impact of COVID-19 on the global Gastrointestinal Therapeutics market. The report considers 2018-2020 historic period, 2021 as base year, and 2022-2028 as forecast period. The report includes quantitative analysis of the market supported by the mar-ket drivers, challenges, and trends to accurately map the market scenario and competition.
Gastrointestinal Therapeutics market report is based on robust research methodology designed using blend of research ap-proaches developed using secondary/desk research and validated through the primary research and expert insights. Eternity Insights also uses paid data bases such as FACIVA, Hoovers, and other bench-marking and forecasting tools to provide accurate statistical analysis of supply and demand trends.
To learn more about this report
Key Research Highlights: Market Drivers
The Gastrointestinal Therapeutics market is estimated to expand at a considerable growth rate during the forecast period ow-ing to increasing prevalence of venous diseases and increasing new product approvals to cater this demand. Rise in the awareness about the diseases, increasing importance of early diagnosis, and growing spending on chronic diseases are poised to boost the market growth. Moreover, the key players in the market are investing in research and development of technologically advanced products leading to increased utilization of the Gastrointestinal Therapeutics products across developed and developing countries of the world.
Key Research Highlights: Market Restrains
Limited awareness about the diseases, high cost of products, low economical condition, and lack of favorable insurance systems restricts the adoption of Gastrointestinal Therapeutics products across developing regions of the globe. However, launch of new products with low cost and increasing efforts for market penetration in these regions can offer lucrative growth opportunities for the players in the Gastrointestinal Therapeutics market.
To learn more about this report
Key Research Highlights: Trends
Increasing research and development spending on Gastrointestinal Therapeutics development has been the leading industry trend of Gastrointestinal Therapeutics market
The leading players in the market are focused on developing products which are cost effective and high quality to tap the huge unaddressed opportunities in the developing regions. This can be wit-nessed from the increasing spending on research and development and growing number of new product approvals.
Global Gastrointestinal Therapeutics Market Size, 2018-2028 (USD MILLION)
To learn more about this report
Market Segmentation
| Report Attributes |
Details |
| The market size value in 2021 |
USD XX.XX Million |
| CAGR (2021 - 2028) |
XX.XX % |
| The Revenue forecast in 2028 |
USD XX.XX Million |
| Base year for estimation |
2021 |
| Historical data |
2018-2019 |
| Forecast period |
2022-2028 |
| Quantitative units |
- Revenue in USD Million
- CAGR from 2021 to 2028
|
| Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered |
By Type Outlook, Application Outlook, Regional Outlook |
| By Type Outlook |
Tablets,Injection, Other |
| By Application Outlook |
IBD,Irritable Bowel Syndrome (IBS),Other |
| Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Country scope |
U.S., Canada, U.K., Germany, France, BENELUX, China, India, Japan, South Korea, Brazil, Saudi Arabia, UAE, Turkey |
| Key companies profiled |
Johnson & Johnson,AbbVie,Allergan,Takeda,Novartis,Pfizer,GlaxoSmithKline,Merck,UCB (Belgium),F. Hoffmann-La Roche,Eli Lilly,AstraZeneca,Procter & Gamble,Eisai,Shire Pharmaceuticals,Ferring Pharmaceuticals,Kyowa Hakko Kirin,Salix Pharmaceuticals,Ono Pharmaceutical,TSD Japan,RedHill Biopharma,Kaken Pharmaceutical,Amgen,Synergy Pharmaceuticals,Ajinomoto,Kissei Pharmaceutical,Hutchison Medi Pharma |
| Customization Available |
Yes, the report can be tailored to meet your specific requirements. |
Key Market Players
- Johnson & Johnson
- AbbVie
- Allergan
- Takeda
- Novartis
- Pfizer
- GlaxoSmithKline
- Merck
- UCB (Belgium)
- F. Hoffmann-La Roche
- Eli Lilly
- AstraZeneca
- Procter & Gamble
- Eisai
- Shire Pharmaceuticals
- Ferring Pharmaceuticals
- Kyowa Hakko Kirin
- Salix Pharmaceuticals
- Ono Pharmaceutical
- TSD Japan
- RedHill Biopharma
- Kaken Pharmaceutical
- Amgen
- Synergy Pharmaceuticals
- Ajinomoto
- Kissei Pharmaceutical
- Hutchison Medi Pharma
Gastrointestinal Therapeutics Market, By Type
Gastrointestinal Therapeutics Market, By Application
- IBD
- Irritable Bowel Syndrome (IBS)
- Other
Key Benefits To The Stake Holders
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) and volume (Tons) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Table Of Contents
Table of Contents
Global Gastrointestinal Therapeutics Market by Manufacturers, Regions, Type and Application, Forecast to 2026
1 Report Overview
1.1 Definition and Specification
1.2 Report Overview
1.2.1 Manufacturers Overview
1.2.2 Regions Overview
1.2.3 Type Overview
1.2.4 Application Overview
1.3 Industrial Chain
1.3.1 Gastrointestinal Therapeutics Overall Industrial Chain
1.3.2 Upstream
1.3.3 Downstream
1.4 Industry Situation
1.4.1 Industrial Policy
1.4.2 Product Preference
1.4.3 Economic/Political Environment
1.5 SWOT Analysis
2 Market Assessment by Type
2.1 Tablets Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.2 Injection Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
3 Asia Pacific Gastrointestinal Therapeutics Market Assessment by Type
3.1 Asia Pacific Market Performance (Sales, Revenue)
3.2 Key Players in Asia Pacific
4 North America Gastrointestinal Therapeutics Market Assessment by Type
4.1 North America Market Performance (Sales, Revenue)
4.2 Key Players in North America
5 Europe Gastrointestinal Therapeutics Market Assessment by Type
4.1 Europe Market Performance (Sales, Revenue)
4.2 Key Players in Europe
6 South America Gastrointestinal Therapeutics Market Assessment by Type
4.1 South America Market Performance (Sales, Revenue)
4.2 Key Players in South America
7 Middle Easr and Africa Gastrointestinal Therapeutics Market Assessment by Type
4.1 Middle Easr and Africa Market Performance (Sales, Revenue)
4.2 Key Players in Middle Easr and Africa
8 World Gastrointestinal Therapeutics Market Assessment by Type
8.1 Asia Pacific Gastrointestinal Therapeutics Market Assessment by Application (Consumption and Market Share)
8.2 North America Gastrointestinal Therapeutics Market Assessment by Application (Consumption and Market Share)
8.3 Europe Gastrointestinal Therapeutics Market Assessment by Application (Consumption and Market Share)
8.4 South America Gastrointestinal Therapeutics Market Assessment by Application (Consumption and Market Share)
8.5 Middle East and Africa Gastrointestinal Therapeutics Market Assessment by Application (Consumption and Market Share)
9 Company Profiles/Analysis
9.1 Johnson & Johnson
9.1.1 Johnson & Johnson Profiles
9.1.2 Johnson & Johnson Product Portfolio
9.1.3 Johnson & Johnson Gastrointestinal Therapeutics Business Performance
9.1.4 Johnson & Johnson Gastrointestinal Therapeutics Business Development and Market Status
9.2 AbbVie
9.2.1 AbbVie Profiles
9.2.2 AbbVie Product Portfolio
9.2.3 AbbVie Gastrointestinal Therapeutics Business Performance
9.2.4 AbbVie Gastrointestinal Therapeutics Business Development and Market Status
9.3 Allergan
9.3.1 Allergan Profiles
9.3.2 Allergan Product Portfolio
9.3.3 Allergan Gastrointestinal Therapeutics Business Performance
9.3.4 Allergan Gastrointestinal Therapeutics Business Development and Market Status
9.4 Takeda
9.4.1 Takeda Profiles
9.4.2 Takeda Product Portfolio
9.4.3 Takeda Gastrointestinal Therapeutics Business Performance
9.4.4 Takeda Gastrointestinal Therapeutics Business Development and Market Status
9.5 Novartis
9.5.1 Novartis Profiles
9.5.2 Novartis Product Portfolio
9.5.3 Novartis Gastrointestinal Therapeutics Business Performance
9.5.4 Novartis Gastrointestinal Therapeutics Business Development and Market Status
9.6 Pfizer
9.6.1 Pfizer Profiles
9.6.2 Pfizer Product Portfolio
9.6.3 Pfizer Gastrointestinal Therapeutics Business Performance
9.6.4 Pfizer Gastrointestinal Therapeutics Business Development and Market Status
9.7 GlaxoSmithKline
9.7.1 GlaxoSmithKline Profiles
9.7.2 GlaxoSmithKline Product Portfolio
9.7.3 GlaxoSmithKline Gastrointestinal Therapeutics Business Performance
9.7.4 GlaxoSmithKline Gastrointestinal Therapeutics Business Development and Market Status
9.8 Merck
9.8.1 Merck Profiles
9.8.2 Merck Product Portfolio
9.8.3 Merck Gastrointestinal Therapeutics Business Performance
9.8.4 Merck Gastrointestinal Therapeutics Business Development and Market Status
9.9 UCB (Belgium)
9.9.1 UCB (Belgium) Profiles
9.9.2 UCB (Belgium) Product Portfolio
9.9.3 UCB (Belgium) Gastrointestinal Therapeutics Business Performance
9.9.4 UCB (Belgium) Gastrointestinal Therapeutics Business Development and Market Status
9.10 F. Hoffmann-La Roche
9.10.1 F. Hoffmann-La Roche Profiles
9.10.2 F. Hoffmann-La Roche Product Portfolio
9.10.3 F. Hoffmann-La Roche Gastrointestinal Therapeutics Business Performance
9.10.4 F. Hoffmann-La Roche Gastrointestinal Therapeutics Business Development and Market Status
9.11 Eli Lilly
9.12 AstraZeneca
9.13 Procter & Gamble
9.14 Eisai
9.15 Shire Pharmaceuticals
9.16 Ferring Pharmaceuticals
9.17 Kyowa Hakko Kirin
9.18 Salix Pharmaceuticals
9.19 Ono Pharmaceutical
9.20 TSD Japan
9.21 RedHill Biopharma
9.22 Kaken Pharmaceutical
9.23 Amgen
9.24 Synergy Pharmaceuticals
9.25 Ajinomoto
9.26 Kissei Pharmaceutical
9.27 Hutchison Medi Pharma
10 World Gastrointestinal Therapeutics Market Assessment by Players
10.1 Global Gastrointestinal Therapeutics Sales (K Units) and Market Share by Players 2014-2020
10.2 Global Gastrointestinal Therapeutics Revenue (M USD) and Market Share by Players 2014-2020
10.3 Global Gastrointestinal Therapeutics Price (USD/Unit) of Players 2014-2020
10.4 Global Gastrointestinal Therapeutics Gross Margin of Players 2014-2020
10.5 Market Concentration
11 Regional Market Performance by Segment of Players
11.1 North America
11.1.1 North America Gastrointestinal Therapeutics Sales Assessment of Players 2014-2020
11.1.2 North America Gastrointestinal Therapeutics Revenue Assessment of Players 2014-2020
11.1.3 North America Gastrointestinal Therapeutics Price Assessment of Players 2014-2020
11.1.4 North America Gastrointestinal Therapeutics Gross Margin Assessment of Players 2014-2020
11.1.5 Market Concentration
11.2 Europe
11.2.1 Europe Gastrointestinal Therapeutics Sales Assessment of Players 2014-2020
11.2.2 Europe Gastrointestinal Therapeutics Revenue Assessment of Players of Manufacturers 2014-2020
11.2.3 Europe Gastrointestinal Therapeutics Price Assessment of Players 2014-2020
11.2.4 Europe Gastrointestinal Therapeutics Gross Margin Assessment of Players 2014-2020
11.2.5 Market Concentration
11.3 Asia-Pacific Market Performance for Manufacturers
11.3.1 Asia-Pacific Gastrointestinal Therapeutics Sales Assessment of Players 2014-2020
11.3.2 Asia-Pacific Gastrointestinal Therapeutics Revenue Assessment of Players 2014-2020
11.3.3 Asia-Pacific Gastrointestinal Therapeutics Price Assessment of Players 2014-2020
11.3.4 Asia-Pacific Gastrointestinal Therapeutics Gross Margin Assessment of Players 2014-2020
11.3.5 Market Concentration
11.4 South America Market Performance for Players
11.4.1 South America Gastrointestinal Therapeutics Sales Assessment of Players 2014-2020
11.4.2 South America Gastrointestinal Therapeutics Revenue Assessment of Players 2014-2020
11.4.3 South America Gastrointestinal Therapeutics Price Assessment of Players 2014-2020
11.4.4 South America Gastrointestinal Therapeutics Gross Margin Assessment of Players 2014-2020
11.4.5 Market Concentration
11.5 Middle East and Africa Market Performance for Players
11.5.1 Middle East and Africa Gastrointestinal Therapeutics Sales Assessment of Players 2014-2020
11.5.2 Middle East and Africa Gastrointestinal Therapeutics Revenue Assessment of Players 2014-2020
11.5.3 Middle East and Africa Gastrointestinal Therapeutics Price Assessment of Players 2014-2020
11.5.4 Middle East and Africa Gastrointestinal Therapeutics Gross Margin Assessment of Players 2014-2020
11.5.5 Market Concentration
12 Regional Market Performance by Segment of Countries
12.1 Asia Pacific
12.1.1 Asia Pacific Gastrointestinal Therapeutics Sales by Countries/Regions 2014-2020
12.1.2 Asia Pacific Gastrointestinal Therapeutics Revenue by Countries/Regions 2014-2020
12.1.3 Asia Pacific Gastrointestinal Therapeutics Average Price by Countries/Regions 2014-2020
12.2 North America
12.2.1 North America Gastrointestinal Therapeutics Sales by Countries/Regions 2014-2020
12.2.2 North America Gastrointestinal Therapeutics Revenue by Countries/Regions 2014-2020
12.2.3 North America Gastrointestinal Therapeutics Average Price by Countries/Regions 2014-2020
12.3 Europe
12.3.1 Europe Gastrointestinal Therapeutics Sales by Countries/Regions 2014-2020
12.3.2 Europe Gastrointestinal Therapeutics Revenue by Countries/Regions 2014-2020
12.3.3 Europe Gastrointestinal Therapeutics Average Price by Countries/Regions 2014-2020
12.4 South America
12.4.1 South America Gastrointestinal Therapeutics Sales by Countries/Regions 2014-2020
12.4.2 South America Gastrointestinal Therapeutics Revenue by Countries/Regions 2014-2020
12.4.3 South America Gastrointestinal Therapeutics Average Price by Countries/Regions 2014-2020
12.5 Middle East and Africa
12.5.1 Middle East and Africa Gastrointestinal Therapeutics Sales by Countries/Regions 2014-2020
12.5.2 Middle East and Africa Gastrointestinal Therapeutics Revenue by Countries/Regions 2014-2020
12.5.3 Middle East and Africa Gastrointestinal Therapeutics Average Price by Countries/Regions 2014-2020
13 Technology and Opportunity
13.1 Technology
13.2 Market Opportunity
14 World Gastrointestinal Therapeutics Sales & Revenue Forecast 2021-2026
14.1 World Gastrointestinal Therapeutics Sales and Revenue Forecast by Regions 2021-2026
14.1.1 World Gastrointestinal TherapeuticsSales and Market Share by Regions
14.1.2 World Gastrointestinal TherapeuticsRevenue and Market Share by Regions
15 Asia Gastrointestinal Therapeutics Market Forecast 2021-2026
15.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
15.1.1 Tablets
15.1.2 Injection
15.2 Consumption Forecast by Application, 2021-2026
16 North America Gastrointestinal Therapeutics Market Forecast 2021-2026
16.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
16.1.1 Tablets
16.1.2 Injection
16.2 Consumption Forecast by Application, 2021-2026
17 Europe Gastrointestinal Therapeutics Market Forecast 2021-2026
17.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
17.1.1 Tablets
17.1.2 Injection
17.2 Consumption Forecast by Application, 2021-2026
18 South America Gastrointestinal Therapeutics Market Forecast 2021-2026
18.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
18.1.1 Tablets
18.1.2 Injection
18.2 Consumption Forecast by Application, 2021-2026
19 Middle East and Africa Gastrointestinal Therapeutics Market Forecast 2021-2026
19.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
19.1.1 Tablets
19.1.2 Injection
19.2 Consumption Forecast by Application, 2021-2026
20 Price (USD/Unit) and Gross Profit Forecast
20.1 Global Gastrointestinal Therapeutics Price (USD/Unit) Trend 2021-2026
20.2 Global Gastrointestinal Therapeutics Gross Profit Trend 2021-2026
21 Conclusion
